What Is the World to Do About Gene-Editing?
By Stephen Buranyi,
The New York Review of Books
| 03. 21. 2019
When the journal Science chose the radical gene-editing technology CRISPR as its 2015 breakthrough of the year, the editorial team closed its description on a dire note. “For better or worse, we all now live in CRISPR’s world,” they wrote. Emerging into the public consciousness in 2013, CRISPR has been with us only as long as it takes to complete secondary school, but like the information technologies that rose alongside it, it is often described as if it is beyond regulation and direction, as if it had acquired its own uncompromising telos.
CRISPR works by repurposing parts of an ancient bacterial immune system to make the job of editing genes in almost any organism unprecedentedly simple and accurate. So simple, in fact, that unlike other scientific advancements that are perpetually just around the corner, CRISPR entered widespread use almost immediately. Gene-edited mice and zebrafish, classic laboratory models, rapidly gave way to edits in the genomes of livestock such as pigs and cows. Chinese scientists have been running human gene-editing trials since 2016, and the first stateside trials for CRISPR in...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...